title: Cardiology Patient Pages: Antidotes for Bleeding Caused by Novel Oral Anticoagulants.
authors.affiliation: From Emergency Medicine, Thomas Jefferson University, Philadelphia, PA. charles.pollack@jefferson.edu.
authors.forename: Charles V
authors.initials: CV
authors.lastname: Pollack
mesh_terms: D000284:Administration, Oral; D061067:Antibodies, Monoclonal, Humanized / Q000494:pharmacology / Q000627:therapeutic use*; D000991:Antithrombins / Q000009:adverse effects* / Q000627:therapeutic use; D016063:Blood Loss, Surgical / Q000517:prevention & control; D002543:Cerebral Hemorrhage / Q000139:chemically induced / Q000628:therapy; D002986:Clinical Trials as Topic; D000069604:Dabigatran / Q000009:adverse effects* / Q000037:antagonists & inhibitors / Q000276:immunology / Q000627:therapeutic use; D017277:Drug Approval; D004630:Emergencies; D015951:Factor Xa / Q000494:pharmacology / Q000627:therapeutic use*; D065427:Factor Xa Inhibitors / Q000009:adverse effects* / Q000627:therapeutic use; D006470:Hemorrhage / Q000139:chemically induced / Q000188:drug therapy*; D006801:Humans; D011720:Pyrazoles / Q000009:adverse effects* / Q000037:antagonists & inhibitors / Q000627:therapeutic use; D011725:Pyridines / Q000009:adverse effects* / Q000037:antagonists & inhibitors / Q000627:therapeutic use; D011728:Pyridones / Q000009:adverse effects* / Q000037:antagonists & inhibitors / Q000627:therapeutic use; D011994:Recombinant Proteins / Q000494:pharmacology / Q000627:therapeutic use*; D000069552:Rivaroxaban / Q000009:adverse effects* / Q000037:antagonists & inhibitors / Q000627:therapeutic use; D013844:Thiazoles / Q000009:adverse effects* / Q000037:antagonists & inhibitors / Q000627:therapeutic use; D014481:United States; D014486:United States Food and Drug Administration
chemical_list: D061067:Antibodies, Monoclonal, Humanized; D000991:Antithrombins; D065427:Factor Xa Inhibitors; C580915:PRT064445; D011720:Pyrazoles; D011725:Pyridines; D011728:Pyridones; D011994:Recombinant Proteins; D013844:Thiazoles; C522181:apixaban; C000594745:idarucizumab; D000069552:Rivaroxaban; D015951:Factor Xa; D000069604:Dabigatran; C552171:edoxaban